Kidney Cancer

>

Latest News

Addressing Gaps in Education for Non–Clear Cell RCC
Addressing Gaps in Education for Non–Clear Cell RCC

November 19th 2024

A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors

October 22nd 2024

Phase 3 data support benmelstobart/anlotinib as a new potential standard in the frontline treatment of patients with advanced renal cell carcinoma.
Benmelstobart Combo Improves Outcomes Vs Sunitinib in Advanced RCC

September 19th 2024

Belzutifan Yields Sustained Responses, PFS in Advanced Clear Cell RCC | Image Credit: © Rasi - stock.adobe.com.
Belzutifan Yields Sustained Responses, PFS in Advanced Clear Cell RCC

September 13th 2024

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.
Belzutifan Significantly Improves PFS Vs Everolimus in Clear Cell RCC

September 4th 2024

Latest CME Events & Activities

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Register Now!

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

<1
...
2627282930